Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study

Faverio, Paola; Compagnoni, Matteo; Ronco, Raffaella; Franchi, Matteo; Zoppa, Matteo Della; Bonaiti, Giulia; Bonifazi, Martina; Mei, Federico; Luppi, Fabrizio; Pesci, Alberto; Corrao, Giovanni

doi:10.1016/j.jaip.2022.07.029

Cited by 2 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed a discontinuation rate with biologics of 6.5%, comparable to that found in cohorts of adult patients with severe asthma from the same setting (Lombardy, Italy): 2.7% for mepolizumab and 8% for dupilumab 16,17 …”

Section: Discussionsupporting

confidence: 80%

“…Similar results were observed in cohorts of adult patients with severe asthma from the same Italian region (tenfold and fourfold direct costs increase after dupilumab and anti-IL-5 introduction, respectively) and from children from the French national health insurance, in whom 65% of direct healthcare costs were attributed to medications, particularly biologics. 15,16,25 These observations suggest the need for a personalized use of biological drugs to maintain the sustainability of healthcare systems.…”

Section: Discussionmentioning

confidence: 99%

“…Further details on HCU databases in the field of respiratory diseases have been reported elsewhere. [15][16][17][18] The codes of drug therapies and diagnostic procedures used in the current study for drawing records and fields from the aforementioned databases are reported in Table S1.…”

Section: Setting and Data Sourcementioning

confidence: 99%

See 2 more Smart Citations

Healthcare costs and resources utilization in children with difficult‐to‐control asthma treated with biologic therapies: A population‐based cohort study

Monzio Compagnoni,

Conflitti,

Capuano

et al. 2023

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

IntroductionAsthma is one of the most common diseases in children, with a variable range of severity. In recent years, treatment for severe asthma has been largely improved by the availability of targeted biologic therapies. Nevertheless, studies reporting real‐world data and cost‐effectiveness analyses are lacking. The aim of this study was to evaluate, on a population‐based cohort of children with asthma, the impact of the treatment with biologics on healthcare service utilization and associated costs.MethodsData were retrieved from Healthcare Utilization database of Lombardy region (Italy). A cohort of 46 asthmatic children aged 6–11 in treatment with dupilumab, mepolizumab or omalizumab was identified during 2017–2021. We compared healthcare resources use between the year before (“baseline period”) and the year after the treatment initiation (“follow‐up period”). Average 1‐year healthcare costs were also calculated.ResultsComparing the baseline with the follow‐up period, the number of patients with at least one exacerbation‐related hospitalization and ER access decreased by 75.0% and 85.7%, respectively. The use of biologic agents, namely omalizumab, mepolizumab and dupilumab, significantly reduced oral corticosteroids (OCS), short‐acting β2‐agonists and the association inhaled corticosteroids/long‐acting β2‐agonists use. ER admissions for non‐respiratory causes were also significantly reduced, while discontinuation rate was low (6.5%). The overall costs increased, due to the costs of the biologic agents, but the hospital admission‐related costs due to respiratory causes reduced significantly.ConclusionsOur real‐world investigation suggests that biologic agents reduced hospital admissions for respiratory causes and use of anti‐asthmatic drugs, including OCS. However, long‐term healthcare sustainability still needs more in‐depth assessments.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Healthcare costs and resources utilization in children with difficult‐to‐control asthma treated with biologic therapies: A population‐based cohort study

Monzio Compagnoni,

Conflitti,

Capuano

et al. 2023

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recent literature suggested a discontinuation rate, either due to patient's decision, lack of efficacy or adverse events, ranging from 4.7 to 13.4% [4,15]. We observed a discontinuation rate of 8%, in line with other biological drugs for severe asthma recently evaluated in a cohort of patients with similar characteristics (3% for mepolizumab and 9% for benralizumab) [9].…”

Section: Absolute (%) Reduction P-valuesupporting

confidence: 69%

“…The "Materials and methods" section of this manuscript partially overlaps with another study published by our group on the economic impact of anti-IL-5 agents in severe asthma [9].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study

et al. 2023

View full text Add to dashboard Cite

Rationale Severe asthma is burdened by relevant socio-economic and clinical impact. Randomized controlled trials on Dupilumab showed efficacy and a good safety profile, but post-market studies are needed. Objectives To evaluate the impact of Dupilumab on (i) the use of anti-asthmatic drugs, including oral corticosteroids (OCS), (ii) the rates of asthma exacerbation-related hospital admissions, and (iii) the healthcare costs in patients with asthma. Methods Data were retrieved from Healthcare Utilization database of Lombardy region (Italy). We compared healthcare resources use between the 6 months after Dupilumab initiation (“post-intervention period”) and (i) the 6 months before Dupilumab initiation (“wash-out period”) and (ii) the corresponding 6 months of the prior year (“pre-intervention period”). Main results In a cohort of 176 patients, Dupilumab significantly reduced anti-asthmatic drugs use (including OCS and short-acting β2-agonists, inhaled corticosteroids (ICS)/long-acting β2-agonists and ICS alone) when comparing the “pre-intervention” to the “post-intervention” period. When considering hospital admissions, we observed a not statistically or marginally significant reduction between both periods before Dupilumab and the post-intervention period. Six-months discontinuation rate was 8%. Overall healthcare costs had a tenfold increase between the “pre-intervention” and “post-intervention” period, which was mainly led by the biologic drug cost. Conversely, expenditures connected to hospital admissions did not change. Conclusions Our real-world investigation suggests that Dupilumab reduced anti-asthmatic drugs use, including OCS, in comparison to a corresponding period in the prior year. However, long-term healthcare sustainability remains an open issue.

show abstract

Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study

Cited by 2 publications

References 6 publications

Healthcare costs and resources utilization in children with difficult‐to‐control asthma treated with biologic therapies: A population‐based cohort study

Healthcare costs and resources utilization in children with difficult‐to‐control asthma treated with biologic therapies: A population‐based cohort study

Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study

Contact Info

Product

Resources

About